EMEA-002924-PIP02-23

Opinion/decision on a Paediatric investigation plan (PIP): Rybrevant, amivantamab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Neoplasms benign, malignant and unspecified (incl cysts and polyps), PIP number: P/0166/2024

EMEA-002490-PIP01-18

Opinion/decision on a Paediatric investigation plan (PIP): Ztalmy, Ganaxolone, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0183/2024

EMEA-002042-PIP03-23

EMEA-001039-PIP04-23

Opinion/decision on a Paediatric investigation plan (PIP): Comirnaty, Tozinameran,Tozinameran / famtozinameran,tozinameran/ riltozinameran,raxtozinameran, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0105/2024

EMEA-002746-PIP01-20-M03

EMEA-002736-PIP02-23

Opinion/decision on a Paediatric investigation plan (PIP): Jakavi, Ruxolitinib (phosphate), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0102/2024